# A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No

Source: https://onco.cc/trials/nct03930953/  
OnCo record `nct03930953` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Golcadomide, Rituximab, Obinutuzumab in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.

## Summary

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) is a phase 1/2 interventional study registered as NCT03930953 by Celgene, with 438 participants planned, started 2019-05-20 and due to reach its primary completion in 2027-04-07. Interventions recorded: CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03930953
- Phase: 1/2
- Setting: A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
- Sponsor: Celgene
- Enrolled: 438

## Sources

- ClinicalTrials.gov NCT03930953: https://clinicaltrials.gov/study/NCT03930953

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Golcadomide](https://onco.cc/drugs/golcadomide/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct03930953.json